NEW YORK (GenomeWeb News) – KineMed this week announced the renewal of its non-exclusive research collaboration with Pfizer into metabolic disease, and type 2 diabetes in particular.
The collaboration was originally established in 2013 and calls for KineMed to use its dynamic proteomics technology platform to map the impact of potential drug candidates.
KineMed's technology uses wide-scale isotopic labeling and mass spectrometry to track protein activity kinetics, which can elucidate biological pathways and disease processes.
This marks the second renewal of the two firms' collaboration, following an initial renewal announced in March.